This presentation provides a detailed overview of Managed Entry Agreements (MEAs) for pharmaceutical products. It:
- Describes what products and countries are suitable for performance-based MEAs
- Outlines what makes successful MEAs for pharma companies, payers, and healthcare providers
- Discusses the role of MEAs in the future
Authors for this presentation are:
- Yan Xue, Principal
- Eleanor Berry, Manager
- Kathryn Acheson, Associate Consultant
